Ordinary1 is exactly right. Overall Q3 sales have been very disappointing and have been at the same level of Q1 and Q2.
It is especially disappointing given the time commitments and the increased sales staff they have in the US to sell itrack.
The drop in the share price appears justified.
Ann: Glaucoma Business FY18Q3 Sales Update, page-8
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
0.010(4.65%) |
Mkt cap ! $51.48M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 22.5¢ | 21.8¢ | $137.7K | 624.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 27766 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.5¢ | 34529 | 2 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
22.0¢ |
Change
0.010 ( 2.33 %) |
||||
| Open | High | Low | Volume | ||
| 22.5¢ | 22.5¢ | 21.5¢ | 190801 | ||
| Last updated 15.47pm 14/06/2024 ? | |||||
| EYE (ASX) Chart |